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Abstract 
 
Objective: The objective of this selective EBM review is to determine whether or not 
photodynamic therapy improves the survival rate of patients with unresectable 
cholangiocarcinoma. 
 
Study Design: Systematic review of two randomized controlled trials and one 
retrospective cohort study published in 2014, 2014, and 2016. 
 
Data Sources: Two randomized controlled trials and one retrospective cohort study 
examining photodynamic therapy in patients with unresectable cholangiocarcinoma. Data 
sources were found using PubMed and EBSCOhost. 
 
Outcome(s) Measured: Overall survival and progression free survival were measured in 
patients who underwent photodynamic therapy for unresectable cholangiocarcinoma. 
Each study analyzed overall survival using a Kaplan-Meier survival curve.  
 
Results: The RCT by Hauge et al. found photodynamic therapy to improve overall 
survival rate in patients with unresectable cholangiocarcinoma compared to patients who 
did not receive photodynamic therapy. The RCT by Park et al. found photodynamic 
therapy plus oral flouropyrimidine to improve overall survival over photodynamic 
therapy alone. The retrospective cohort study by Strand et al. was found to show no 
significant difference in overall survival with patients who underwent ERCP-directed 
radiofrequency ablation versus ERCP-directed photodynamic therapy. 
 
Conclusions: There is conflicting evidence as to whether photodynamic therapy 
improves the survival rate of patients with unresectable cholangiocarcinoma. Further  
 
Key Words: Photodynamic therapy, cholangiocarcinoma, overall survival
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INTRODUCTION 
 Cholangiocarcinoma is a rare and debilitating cancer of the biliary tract.  The 
majority of cholangiocarcinoma cases are not detected until metastasis has occurred and 
there is no chance of cure through medical intervention.  The prognosis of a patient with 
cholangiocarcinoma is not good even with early detection and traditional treatment that 
includes chemotherapy and radiation.  This systematic review evaluates two randomized 
controlled trials (RCT) and one retrospective cohort study comparing the efficacy of 
photodynamic therapy with traditional treatment methods for unresectable 
cholangiocarcinoma to traditional treatment methods such as chemotherapy and radiation. 
 Cholangiocarcinoma is a rare cancer that is increasing in incidence every year. 
This aggressive malignancy has about 5,000 newly diagnosed cases each year.1  The 
incidence of cholangiocarcinoma is very high in Southeast Asia, but the number of cases 
are steadily increasing in the United States.  A patient diagnosed with 
cholangiocarcinoma warrants the highest oncologic care available.  High-level care 
comes with a high-level price in hospital equipment, utilities, staff, and medicine.  The 
number of hospital admissions for patients with cholangiocarcinoma was 11,970.2  The 
average length of stay of hospital admissions in 2012 was 7.9 days.2  The majority, if not 
all, of the patient hospital admissions require nurses, physicians, unit clerks, hospital 
rooms, equipment, utilities, and medications which can make each stay exceptionally 
expensive.  In 2012, the average cost for a cholangiocarcinoma patient’s hospital charges 
was $77,753.2   
 The most common location for cholangiocarcinoma is the perihilar region of the 
biliary tract.1  The perihilar area of the biliary tract is the junction where the left hepatic 
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duct and the right hepatic duct join together to form the common bile duct.  Tumors in the 
perihilar location of the biliary tract are known as Klatskin tumors.3  Most patients who 
suffer from cholangiocarcinoma are over the age of 60 and more commonly males.2  
Patients look to seek medial treatment typically for abdominal pain and/or jaundice of 
skin and sclera of the eyes.2  Cholangiocarcinoma coincides with a multitude of 
complications that severely inhibit the quality of life of a patient.  These complications 
include, but are not limited to, cachexia, cholestasis, cholangitis, biliary obstruction, and 
hepatic dysfunction.1 Evaluation of the patient typically involves imaging studies that 
show biliary mass on abdominal ultrasound followed by MRI or magnetic resonance 
cholangiopancreatography (MRCP) and biopsy to diagnose if not confirmed on imaging.2    
 The gold standard of treatment for cholangiocarcinoma is surgical resection of the 
disease.1 However, surgical resection is often not possible because the disease is often 
detected too late for a patient to be a candidate for surgical resection due to metastasis or 
risks outweighing the benefits of the surgery concerning the quality of life of the patient.  
Other standard forms of treatment include biliary stents to alleviate obstruction of the 
biliary tract.  These stents include temporary plastic stents and self-expandable metal 
stents.1 The stents are placed in the biliary tract via endoscopy or interventional radiology 
which is minimally invasive to the patient.1 Typical standards of care for 
cholangiocarcinoma include chemotherapy and radiation.1 Other adjuvant therapies 
include transarterial chemoembolization, percutaneous transhepatic cholangiography 
tubes, transarterial embolization, and liver transplantation. 
 The five-year survival rate of patients with cholangiocarcinoma is approximately 
15%.3  Photodynamic therapy is an ablation therapy that uses localized photosensitization 
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to make the targeted cells become necrotic or induce apoptosis.1  Research has shown 
mixed results of photodynamic therapy improving survival rate of patients with 
unresectable cholangiocarcinoma as isolated therapy.  Research shows that endoscopic 
retrograde cholangiopancreatography (ERCP) with photodynamic therapy is associated 
with improved survival rate compared to only biliary stent placement. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not 
photodynamic therapy improves the survival rate of patients with unresectable 
cholangiocarcinoma. 
METHODS 
 Studies for this EBM were selected based on the population, intervention, 
comparison, outcome, and type of study in each article.  This EBM selected two 
randomized controlled trials (RCT) and one retrospective cohort study that evaluated 
patients between the ages of 35-79 with unresectable cholangiocarcinoma for median 
progression free survival rate and one year survival rate.  Interventions in the studies 
included photodynamic therapy, ERCP directed photodynamic therapy, and 
photodynamic therapy plus biliary stent plus Gemcitabine and Capacitabine (GemCap).  
Comparison groups included Photodynamic therapy plus oral flouropyrimidine, ERCP 
directed radiofrequency ablation, and biliary stent plus GemCap. 
 Data sources were articles found using searches through PubMed and EBSCOhost 
with keywords including “cholangiocarcinoma”, “photodynamic therapy”, and 
“randomized controlled trial”.  All articles selected were published in the English 
language.  Each article was published in a peer-reviewed journal.  The author of this 
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systematic review performed all of the research used in this paper.  The articles were 
selected based on their relevance to the clinical question, “Does photodynamic therapy 
improve the survival rate of patients with unresectable cholangiocarcinoma?”  The 
inclusion criteria for this review was randomized controlled trial or retrospective cohort 
study published after 2012 with patients with unresectable cholangiocarcinoma.  This 
review excluded patients who were under the age of 18 and patients who had resectable 
cholangiocarcinoma.  In order to determine the significance of the results published in the 
articles, the numbers needed to treat (NNT), absolute benefit increase (ABI), relative 
benefit increase (RBI), and p-values were calculated.  One article had continuous data 
that could not be statistically converted but was quantified I median number of days of 
survival.3  One article had a p-value that was recorded, however, this article had 
continuous data that could not be statistically converted and was calculated as median 
number of months survived.1  One article had dichotomous data that listed a p-value.4 
This article had data that was able to have calculations of numbers needed to treat, 
absolute benefit increase, and relative benefit increase. 
Table 1 – Demographics & Characteristics of included studies 
 
Study 
 
Type 
 
# 
Pts 
 
Age 
(yrs) 
 
Inclusion 
Criteria 
 
Exclusion 
Criteria 
 
W/D 
 
Interventions 
Hauge3, 
2016 
RCT 20 35-
75 
Unresectable 
or recurrent/ 
metastatic 
biliary tract 
cancer with 
no previous 
chemo or 
radiation 
therapy, no 
Evidence 
of 
ongoing 
infection 
and life 
expect-
ancy of < 
3 months 
5 Stent, 
temoporfin/ 
photodynamic 
therapy, 
GemCap 
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OUTCOMES MEASURED 
 The outcomes measured in all three studies were patient overall survival after 
treatment with photodynamic therapy.  Studies measured survival time from the day the 
patient entered into the trial until the day of the patient’s death.1,3,4   
 In the article by Strand et al., the primary outcome measured was the overall 
survival of patients in months.  Total months were calculated starting from the time the 
additional 
cancer within 
last 5 years 
Park4, 
2014 
RCT 51 64 + 
11  
Patients with 
locally 
advanced 
unresectable 
hilar 
cholangio-
carcinoma 
with no prior 
chemotherapy 
or 
radiotherapy, 
no serious or 
uncontrolled 
medical 
illness, 
adequate 
bone marrow 
function 
Porphyria 
or 
previous 
placement 
of biliary 
metal 
stent 
8 Photodynamic 
therapy  
Strand1, 
2014 
Retrospective 
Cohort Study 
48 55-
79 
Patients over 
18 years old 
diagnosed 
with 
unresectable 
cholangio-
carcinoma 
Patients 
who were 
capable of 
having 
surgical 
resection 
of 
cholangio-
carcinoma 
0 ERCP directed 
photodynamic 
therapy 
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patient received the intervention until patient death.  Median survival of patients in the 
intervention and comparison groups was analyzed using a Kaplan-Meier survival curve.1 
 In the article by Hauge et al., the outcomes measured were progression free 
survival and overall survival.  Both outcomes were calculated into median number of 
days for both the intervention group and the comparison group.  Ten patients were in 
each group respectively.  The data used to determine outcome measurements was started 
on the day of initial randomization of the study until the day of patient death.  Median 
overall survival was analyzed using a Kaplan-Meier survival curve.3 
 In the article by Park et al., overall survival and progression free survival were 
measured.  The time of data calculation was from the date of randomization until the date 
of patient death for overall survival.  Progression free survival was measured from date of 
randomization until date of death or disease progression.  Overall survival and 
progression free survival were analyzed using two separate Kaplan-Meier curves.4 
RESULTS 
 This systematic review used two RCTs and one retrospective cohort study that 
displayed both continuous and dichotomous data comparing photodynamic therapy 
versus other treatment methods for unresectable cholangiocarcinoma that will be 
discussed later in this review.  Each study had inclusion and exclusion criteria for the 
selection of patients, which can be found in Table 1.   
 In the retrospective cohort study by Strand et al., 48 patients with unresectable 
cholangiocarcinoma agreed and gave consent to be included in this study that received 
ERCP treatment between January 2008 and September 2012 at a tertiary-care academic 
medical center.1 The patients were divided into two groups based on the type of treatment 
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the patient received.  The first group consisted of 16 patients who received ERCP-
directed radiofrequency ablation.1 The second group consisted of 32 patients who 
received ERCP-directed photodynamic therapy.1  At the time of statistical analysis, 4 out 
of 16 patients (25%) were alive in the radiofrequency ablation group.1  The median 
survival of this group was 9.6 months with a confidence interval of 95%.1  The range of 
survival in the group was 5.1-11.7 months.1  At the same time, 0 out of 32 patients (0%) 
were alive in the photodynamic therapy group.1  The median survival of the group was 
7.5 months with a confidence interval of 95%.1  The range of survival in the group was 
4.3-16 months.1  A Kaplan-Meier survival curve analyzed the survival rate of patients 
who received ERCP-directed radiofrequency ablation and ERCP-directed photodynamic 
therapy.  The difference in overall survival between patients of either group was not 
statistically significant with a p-value of 0.799 (see table 2).1   Strand et al also calculated 
an adjusted survival rate for both groups based on factors of age, sex, distant metastasis, 
time between diagnosis and initial treatment, and radiofrequency ablation using the Cox 
proportional hazard model.1 The only variable of that showed a statistically significant 
negative correlation with survival was distant metastasis with a p-value of 0.014.1  
Table 2: Overall survival rate of ERCP-directed therapy1 
Group Overall survival rate P-value 
ERCP-directed 
radiofrequency ablation 
therapy 
 
9.6 months 
 
0.799 
ERCP-directed 
photodynamic therapy 
7.5 months 0.799 
 
 In the RCT by Hauge et al., 20 patients with unresectable cholangiocarcinoma 
agreed and gave consent to participate in the study that took place from June 2008-
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November 2011.3  The 20 patients were randomized into two groups, Arm A and Arm B.  
Arm A consisted of 10 patients who were to receive photodynamic therapy plus a biliary 
stent plus GemCap (Gemcitabine 1000 mg/m2 day 1 and day 8 and Capacitabine 650 
mg/m2 two times a day days 1-14 every third week).3  During the study 3 patients in Arm 
A were unable to receive GemCap due to progression of infection and only received 
photodynamic therapy plus a biliary stent.3  Arm B consisted of 10 patients who were to 
receive GemCap plus a biliary stent.3  During the study two patients withdrew from the 
study and only received a biliary stent due to thrombocytopenia.3  Hauge et al. found that 
Arm A had a median survival rate of 311 days for 7 patients who received photodynamic 
therapy plus stent plus GemCap.3  The range of survival was 178-1060 days.3  Arm B had 
a median survival rate of 336 days for 8 patients who received GemCap plus stent.3  The 
range of survival was 110-690 days.3  Median progression free survival of the 7 Arm A 
patients was 175 days with a range of 90-600 days.3  Arm B had a median progression 
free survival of 96 days with a range of 56-422 days (see table 3).3  Hauge et al. created a 
Kaplan-Meier survival curve to analyze the difference of median overall survival 
between the two groups.  There was no adverse effects to the therapy reported by Hauge 
et al.3  Only 15 patients that were included in the study at time of data collection 
completed the intended therapy without withdrawal or alteration in treatment.3  Statistical 
values were in published in this RCT. 
Table 3: Median overall survival in days3 
Group Median Overall Survival 
Arm A (Photodynamic 
therapy+GemCap+Stent)  
311 days 
Arm B (GemCap+Stent)  336 days 
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 In the RCT by Park et al., 43 patients with unresectable cholangiocarcinoma 
agreed and gave consent to participate in the study that took place from February 2009 to 
May 2012.4  The 43 patients were randomized into two groups.  The first group, Group 
A, had 21 patients and was given photodynamic therapy plus oral flouropyrimidine.4 The 
second group, Group B, had 22 patients was given only photodynamic therapy.4  Park et 
al. found that Group A patients had a one year survival rate of 76.2% compared to 32% 
Group B patients who were given only photodynamic therapy.4  A log-rank test was used 
to evaluate the results which were found to be statistically significant with a p-value of 
0.003.4  The median overall survival of patients in group A was 17 months with a 
confidence interval of 95%.4  Group B median overall survival was 8 months with a 
confidence interval of 95%.4  This data was then analyzed on a Kaplan-Meier curve.  A 
log-rank test was used to evaluate the results which were found to be statistically 
significant with a p-value of 0.005.4   Relative benefit increase (RBI) was calculated to be 
-58% and absolute benefit increase (ABI) was calculated to be -44.2%.  Numbers needed 
to treat (NNT) was calculated to be -2, (see table 4) meaning that for every 2 patients 
treated with photodynamic therapy, one less patient will survive one year after the time 
treatment is started compared to control.  There were no adverse effects in Group B.  In 
group A, 7 patients presented with toxicity (6 non-hematologic, 1 hematologic).4  
Adverse events related to tumor progression in patients such as metastasis.  At the 
conclusion of the follow-up period of the study, 3 patients from Group A were alive and 
1 patient from Group B.4   The overall survival rate of patients treated with photodynamic 
therapy was significantly less than patients treated with photodynamic therapy plus oral 
flouropyrimidine for unresectable cholangiocarcinoma.4 
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   Table 4: Analysis of treatment efficacy and statistical significance4 
Study CER EER RBI ABI NNT P-value 
Park 76.2% 32% -58% -44.2% -2 0.003 
 
DISCUSSION  
 Photodynamic therapy’s mechanism of action requires a photosensitizing agent, 
such as temoporfin, that enters the patient intravenously.5 The photosensitizing agent is 
then exposed to a light source calibrated to a specific wavelength of intensity depending 
on the location of the target tissue.5 This light then creates oxygen with the 
photosensitizing agent to create cellular apoptosis that ultimately leads to cell death.5 
Cancer cells are more susceptible to the oxygen that is generated than normal cells.  
Normal cells do not retain the photosensitizer as long as cancer cells which is why the 
light therapy is administered 1-3 days after the patient is given the photosensitizer.5  The 
light source of the therapy typically comes from a laser.  Adverse effects of 
photodynamic therapy include photosensitivity for up to six weeks after treatment, 
scarring, burns, and pain to affected tissue.5 Photodynamic therapy is considered a 
localized therapy that is contraindicated in cancers that have metastasized and cancers 
that may have too much growth or large surface area.5 The main limitation of therapy is 
that the target site must be close to the skin to be efficient due to the penetrating ability of 
light through the skin. 
 The FDA does not currently approve photodynamic therapy for treatment of 
cholangiocarcinoma as clinical trials are still evaluating the effectiveness of the therapy.5 
The studies that were analyzed in this systematic review had limitations of small sample 
sizes and different comparison groups to the intervention.  Small sample sizes could be 
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attributed to the small number of cases of unresectable cholangiocarcinoma.  Other 
limitations included complications from the cancer such as cholangitis, infection, and 
biliary tract obstruction.1,3,4 
CONCLUSION 
 There is conflicting evidence as to whether photodynamic therapy improves the 
survival rate of patients with unresectable cholangiocarcinoma.  The study by Strand et 
al. reported no statistical significance between survival rates between ERCP-directed 
radiofrequency ablation and ERCP-directed photodynamic therapy.  The RCT by Hauge 
et al. reported progression free survival rate to be greater in patients who received 
photodynamic therapy. The RCT by Park et al. showed that patients who received 
photodynamic therapy plus oral flouropyrimidine had better overall survival than patients 
with photodynamic therapy. 
 Increased study size is suggested for future studies. None of the studies in this 
review exceeded 50 patients that consented to participate. Patients in the studies analyzed 
had various complications from cholangiocarcinoma that skewed the results of the study 
and may have contributed to hasten death in patients that are very difficult to control in 
future studies.  
 Future consideration in the research of photodynamic therapy in unresectable 
cholangiocarcinoma is to increase the size of participants.  Further investigation is 
warranted in the combination of combination therapy of photodynamic therapy with 
different chemotherapy and radiation.  Future study to evaluate photodynamic therapy 
and photodynamic therapy plus adjuvant therapy for unresectable cholangiocarcinoma is 
required to substantiate the results in this review.
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